FIGURE 4.

Pharmacokinetic (PK) model simulations of the impact of pregnancy, continuation of infliximab (IFX) in the third trimester, and anti‐IFX antibodies on IFX concentration (C_IFX)‐time profiles for women for typical induction and maintenance IFX therapy (5 mg/kg, 65 kg body weight) in absence of pregnancy, and during pregnancy with discontinuation of IFX therapy in the third trimester, that is, Weeks 48–62 (IFX‐stop) or without discontinuation (IFX‐cont) (a) without anti‐IFX antibody formation (ADA−) and (b) with anti‐IFX antibody formation (ADA+). Time of conception was set to week 22 and time of delivery was Week 62